Page 148 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $13.65
52wk Low $3.80 PDS Biotechnology Corpora PDSB $6.42
25B Vreeland Road
Florham Park, NJ 07932

(USD - in millions) www.pdsbiotech.com
Market Cap 196.3
Enterprise 165.6
Basic Shares Out. 31.11 COMPANY OVERVIEW
Float 29.73
Institutional Holdings 25.33% Detailed Analysis:Channelchek.com
Short Interest 5.52
Avg. 90-Day Volume 0.48 PDS Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune® and
Infectimune™ T cell-activating technology platforms. We believe our
EPS Data targeted Versamune® based candidates have the potential to
overcome the limitations of current immunotherapy by inducing large
2021 2022 2023 quantities of high-quality, potent polyfunctional tumor specific CD4+
CQ1 (0.14) (0.32) (0.32) helper and CD8+ killer T cells.
CQ2 (0.22) (0.20) (0.37)

CQ3 (0.23) (0.26) (0.35)
CQ4 (0.23) (0.67) (0.42)
CY (0.65) (1.43) (1.46) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.79
ROE (ttm) -143.08
Debt-to-Total Cap. (mrq) 49.09
Fiscal Year End 31-Dec
25B Vreeland Florham Park NJ 07932

Key Executives
CEO: Bedu-Addo, Frank
CFO: Hill, Matthew
COO: N/A
IR: Randolph, Deanne
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures